Guillermo Martinez de Tejada

List of Publications by Year in Descending Order

51 papers	1,477 citations	23 h-index	37 g-index
53 ext. papers	1,723 ext. citations	5.3 avg, IF	4.1 L-index

#	Paper	IF	Citations
51	Antimicrobial Peptides in the Battle against Orthopedic Implant-Related Infections: A Review. *Pharmaceutics*, **2021**, 13,	6.4	2
50	Cathelicidin and PMB neutralize endotoxins by multifactorial mechanisms including LPS interaction and targeting of host cell membranes. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	3
49	Activity of Anti-Microbial Peptides (AMPs) against and Other Parasites: An Overview. *Biomolecules*, **2021**, 11,	5.9	4
48	An update on endotoxin neutralization strategies in Gram-negative bacterial infections. *Expert Review of Anti-Infective Therapy*, **2021**, 19, 495-517	5.5	2
47	An antibiotic potentiator retains its activity after being immobilized on silicone and prevents growth of multidrug-resistant Pseudomonas aeruginosa biofilms. *Materials Science and Engineering C*, **2021**, 121, 111876	8.3	3
46	Anti-Infective and Anti-Inflammatory Mode of Action of Peptide 19-2.5. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
45	Permeability enhancers sensitize lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to lactamase inhibitors, thereby restoring their lactam susceptibility. *International Journal of Antimicrobial Agents*, **2020**, 56, 105986	14.3	10
44	A synthetic peptide sensitizes multi-drug resistant Pseudomonas aeruginosa to antibiotics for more than two hours and permeabilizes its envelope for twenty hours. *Journal of Biomedical Science*, **2020**, 27, 85	13.3	4
43	LPS-neutralizing peptides reduce outer membrane vesicle-induced inflammatory responses. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2019**, 1864, 1503-1513	5	19
42	Antibacterial action of synthetic antilipopolysaccharide peptides (SALP) involves neutralization of both membrane-bound and free toxins. *FEBS Journal*, **2019**, 286, 1576-1593	5.7	9
41	A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant Pseudomonas aeruginosa strains. *Scientific Reports*, **2019**, 9, 3452	4.9	30
40	AMPs as Anti-biofilm Agents for Human Therapy and Prophylaxis. *Advances in Experimental Medicine and Biology*, **2019**, 1117, 257-279	3.6	18
39	Synthetic Anti-lipopolysaccharide Peptides (SALPs) as Effective Inhibitors of Pathogen-Associated Molecular Patterns (PAMPs). *Advances in Experimental Medicine and Biology*, **2019**, 1117, 111-129	3.6	4
38	Development of Antimicrobial Peptides Based on Limulus Anti-Lipopolysaccharide Factor (LALF) **2019**, 683-706		
37	Inactivation of Bacteria by rradiation to Investigate the Interaction with Antimicrobial Peptides. *Biophysical Journal*, **2019**, 117, 1805-1819	2.9	5
36	Inhibition of Lipopolysaccharide- and Lipoprotein-Induced Inflammation by Antitoxin Peptide Pep19-2.5. *Frontiers in Immunology*, **2018**, 9, 1704	8.4	28
35	Antimicrobial endotoxin-neutralizing peptides promote keratinocyte migration via P2X7 receptor activation and accelerate wound healing in vivo. *British Journal of Pharmacology*, **2018**, 175, 3581-3593	8.6	14

34	Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits. *Experimental and Molecular Medicine*, **2017**, 49, e345	12.8	11
33	Antimicrobial Peptides as Anti-biofilm Agents in Medical Implants. *Current Topics in Medicinal Chemistry*, **2017**, 17, 590-603	3	19
32	Antimicrobial activity of synthetic cationic peptides and lipopeptides derived from human lactoferricin against Pseudomonas aeruginosa planktonic cultures and biofilms. *BMC Microbiology*, **2015**, 15, 137	4.5	51
31	Novel integrated and portable endotoxin detection system based on an electrochemical biosensor. *Analyst, The*, **2015**, 140, 654-60	5	21
30	Lipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides. *Scientific Reports*, **2015**, 5, 14292	4.9	40
29	Therapeutical Administration of Peptide Pep19-2.5 and Ibuprofen Reduces Inflammation and Prevents Lethal Sepsis. *PLoS ONE*, **2015**, 10, e0133291	3.7	8
28	Implementation and Characterization of a Fully Miniaturized Biosensor for Endotoxin Detection Based on Electrochemical Techniques. *IEEE Sensors Journal*, **2014**, 14, 270-277	4	8
27	Screening and selection of synthetic peptides for a novel and optimized endotoxin detection method. *Journal of Biotechnology*, **2014**, 186, 162-8	3.7	10
26	Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1480-7	5.9	64
25	Bacterial cell wall compounds as promising targets of antimicrobial agents II. Immunological and clinical aspects. *Current Drug Targets*, **2012**, 13, 1131-7	3	7
24	Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines. *Current Drug Targets*, **2012**, 13, 1121-30	3	45
23	Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. *Biophysical Journal*, **2011**, 100, 2652-61	2.9	92
22	Structural features governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against Pseudomonas aeruginosa in vitro and in vivo. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 218-28	5.9	40
21	Effective Antimicrobial and Anti-Endotoxin Activity of Cationic Peptides Based on Lactoferricin: A Biophysical and Microbiological Study. *Anti-Infective Agents in Medicinal Chemistry*, **2010**, 9, 9-22		9
20	New antiseptic peptides to protect against endotoxin-mediated shock. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3817-24	5.9	93
19	Structural prerequisites for endotoxic activity in the Limulus test as compared to cytokine production in mononuclear cells. *Innate Immunity*, **2010**, 16, 39-47	2.7	44
18	Candida albicans enhances experimental hepatic melanoma metastasis. *Clinical and Experimental Metastasis*, **2010**, 27, 35-42	4.7	12
17	Physicochemical and biological characterization of anti-endotoxin peptides and their influence on lipid properties. *Protein and Peptide Letters*, **2010**, 17, 1328-33	1.9	8

16	Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation. *Journal of Biological Chemistry*, **2009**, 284, 19493-500	5.4	36
15	Comparative analysis of selected methods for the assessment of antimicrobial and membrane-permeabilizing activity: a case study for lactoferricin derived peptides. *BMC Microbiology*, **2008**, 8, 196	4.5	37
14	Rationale for the design of shortened derivatives of the NK-lysin-derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens. *Journal of Biological Chemistry*, **2007** , 282, 14719-28	5.4	64
13	The acyl group as the central element of the structural organization of antimicrobial lipopeptide. *Journal of the American Chemical Society*, **2007**, 129, 1022-3	16.4	39
12	Influence of N-acylation of a peptide derived from human lactoferricin on membrane selectivity. *Biochimica Et Biophysica Acta - Biomembranes*, **2006**, 1758, 1426-35	3.8	40
11	Comparing Antimicrobial and Membrane Permeabilizing Activity of Peptides Derived from Human Cationic Proteins **2006**, 255-257		
10	Effect of asymptomatic natural infections due to common mouse pathogens on the metastatic progression of B16 murine melanoma in C57BL/6 mice. *Clinical and Experimental Metastasis*, **2005**, 22, 549-58	4.7	18
9	Evaluation of the role of the Bvg intermediate phase in Bordetella pertussis during experimental respiratory infection. *Infection and Immunity*, **2005**, 73, 748-60	3.7	38
8	Cyclic antimicrobial peptides based on Limulus anti-lipopolysaccharide factor for neutralization of lipopolysaccharide. *Biochemical Pharmacology*, **2004**, 68, 1297-307	6	59
7	Comparative phenotypic analysis of the Bordetella parapertussis isolate chosen for genomic sequencing. *Infection and Immunity*, **2002**, 70, 3777-84	3.7	37
6	Cavitary pneumonia in an AIDS patient caused by an unusual Bordetella bronchiseptica variant producing reduced amounts of pertactin and other major antigens. *Journal of Clinical Microbiology*, **2002**, 40, 3146-54	9.7	23
5	Human but not ovine isolates of Bordetella parapertussis are highly clonal as determined by PCR-based RAPD fingerprinting. *Infection*, **1998**, 26, 270-3	5.8	20
4	Neither the Bvg- phase nor the vrg6 locus of Bordetella pertussis is required for respiratory infection in mice. *Infection and Immunity*, **1998**, 66, 2762-8	3.7	78
3	Comparative analysis of the virulence control systems of Bordetella pertussis and Bordetella bronchiseptica. *Molecular Microbiology*, **1996**, 22, 895-908	4.1	95
2	The outer membranes of Brucella spp. are resistant to bactericidal cationic peptides. *Infection and Immunity*, **1995**, 63, 3054-61	3.7	109
1	The outer membranes of Brucella spp. are not barriers to hydrophobic permeants. *Journal of Bacteriology*, **1993**, 175, 5273-5	3.5	43